Avid Bioservices Inc (CDMO)

[north40000]

The New York Times article/opinion piece cheynew posted a short time ago provides a response that is more eloquent than I could provide, Vin. I have no doubt that BMY continues now to look for combination therapy molecules to combine with Opdivo, just as AZN/PPHM are doing for Durvalumumab. The reason is expressed here, in case you missed it:


http://www.nytimes.com/2016/08/09/opinion/cancer-drug-ads-vs-cancer-drug-reality.html?action=click&pgtype=Homepage&clickSource=story-heading&module=opinion-c-col-right-region®ion=opinion-c-col-right-region&WT.nav=opinion-c-col-right-region&_r=1

See also the Forbes interviews with BMY executives last Friday, August 5.